BIRC3 and BIRC5: multi-faceted inhibitors in cancer
Frazzi, Raffael. BIRC3 and BIRC5: multi-faceted inhibitors in cancer. Cell & Bioscience 11, Article number: 8(2021)
- Categories
- Reviews
Frazzi, Raffael. BIRC3 and BIRC5: multi-faceted inhibitors in cancer. Cell & Bioscience 11, Article number: 8(2021)
Srour, M., et al. Gene expression comparison between primary estrogen receptor-positive and triple-negative breast cancer with paired axillary lymph node metastasis. Breast J. 2021 JAN 19. Jan 19. doi: 10.1111/tbj.14119. Online ahead of print
Servetto, A., et al. A review of the use of Next Generation Sequencing methodologies to identify biomarkers of resistance to CKK4/6 inhibitors in ER+/HER2-breast cancer. Science Direct December 2020 DEC 9, 103191
Cohen, E. N., et al. Antigen-agnostic microfluidics-based Circulating tumor cell enrichment and downstream molecular characterization. PLoS One. 2020 Oct 23;15(10):e0241123. doi: 10.1371/journal.pone.0241123. eCollection 2020.
Finn, R., et al. Treatment effect of palbociclib plus endocrine therapy by prognostic and intrinsic subtype and biomarker analysis in patients with bone-only disease: a joint analysis of PALOMA-2 AND paloma-3 clinical trials. Breast Cancer Research and Treatment. 2020 AUG 11; https://doi.org/10.1007/s10549-020-05782-4
Karn, T., et al. Tumor mutational burden and immune infiltration as independent predictors of response to neoadjuvant immune checkpoint inhibition in early TNBC in GerparNuevo. Annals of Oncology 2020 May 24; https://doi.org/10.1016/j.annonc.2020.05.015. In Press, Journal Pre-proof Online.
Hierro, C., et al. FGFR1-4 High mRNA Expression (mRNAh) as Predictive Biomarker for FGFR Inhibitors in Breast Cancer (BC). Annals of Oncology 2020 MAR:31(S1),S8-S9., Abstract 29P.
Martin, M., et al., Results from PEARL study (GEICAM/2013-02_CECOG/BC.1.3.006): A phase 3 trial of Palbociclib (PAL) in combination with endocrine therapy (ET versus Capecitabine (CAPE) in hormonal receptor (HR)-positive/human epidermal growth factor receptor (HER) 2-negative metastatic breast cancer (MBC) patients (pts) whose disease progressed on aromatase inhibitors (AIs). Paper presented at San Antonio Breast Cancer Symposium; 2019 December 10-14; San Antonio, Texas. Session GS2.
Srour, M. et al. Gene expression comparison between primary triple-negative breast cancer and matched axillary lymph node metastasis. Poster session presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; 2019 Jun 2, Chicago, IL.
Download pdf 1.2MB
View External Link
Chandarlapaty, S., et al. Cyclin E mRNA: Assessing Cyclin-Dependent Kinase (CDK) Activation State to Elucidate Breast Cancer Resistance to CDK4/6 Inhibitors. Journal of Clinical Oncology 2019 Mar 28; 37(14):1148-11550. Editorial
Sinn, B.V., et al. Pre-therapeutic PD-L1 expression and dynamics of Ki-67 and gene expression during neoadjuvant immune-checkpoint blockade and chemotherapy to predict response within the GeparNuevo trial. Abstract PD5-05 presented at: American Association for Cancer Research Breast Symposium; December 4-8, 2019. San Antonio, Texas.
Loibl, S., et al. Randomized phase II neoadjuvant study (GepartNuevo) to investigate the addition of durvalumab to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC). Clinical Science Symposium Presented at: American Society of Clinical Oncology (ASCO); 2018 June 2, Chicago, IL.
Page last updated May 22, 2023